Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Integr Biol (Camb). 2013 Jan;5(1):66-73. doi: 10.1039/c2ib20117h.
The Nanotechnology Characterization Laboratory's (NCL) unique set-up has allowed our lab to handle and test a variety of nanoparticle platforms intended for the delivery of cancer therapeutics and/or imaging contrast agents. Over the last six years, the NCL has characterized more than 250 different nanomaterials from more than 75 different investigators. These submitted nanomaterials stem from a range of backgrounds and experiences, including government, academia and industry. This has given the NCL a unique and valuable opportunity to observe trends in nanoparticle safety and biocompatibility, as well as note some of the common mistakes and oversights of nanoformulation. While not exhaustive, this article aims to share some of the most common pitfalls observed by the NCL as they relate to nanoparticle synthesis, purification, characterization and analysis.
纳米技术表征实验室（NCL）独特的设置使我们的实验室能够处理和测试各种旨在输送癌症治疗剂和/或成像对比剂的纳米颗粒平台。在过去的六年中，NCL 已经对来自 75 多位不同研究人员的 250 多种不同纳米材料进行了表征。这些提交的纳米材料来自于政府、学术界和工业界等不同背景和经验。这使 NCL 有机会观察纳米颗粒安全性和生物相容性方面的趋势，并注意到纳米配方的一些常见错误和疏忽。虽然不全面，但本文旨在分享 NCL 在纳米颗粒合成、纯化、表征和分析方面观察到的一些最常见的陷阱。
